Cargando…
Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
BACKGROUND AND OBJECTIVES: Deescalation strategies omitting anthracyclines (AC) have been explored in early human epidermal growth factor receptor 2-positive breast cancer (HER2+ EBC), showing similar efficacy regarding pathological complete response (pCR) and long-term outcomes as AC-containing reg...
Autores principales: | de Pinho, Inês Soares, Luz, Paulo, Alves, Lucy, Lopes-Brás, Raquel, Patel, Vanessa, Esperança-Martins, Miguel, Gonçalves, Lisa, Freitas, Ritas, Simão, Diana, Galnares, Maria Roldán, Fernandes, Isabel, Criado, Silvia Artacho, Casado, Salvador Gamez, Cañada, Jose Baena, Vega, Isabel M. Saffie, Costa, João G., Fernandes, Ana S., de Sousa, Rita Teixeira, Costa, Luís |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514156/ https://www.ncbi.nlm.nih.gov/pubmed/37479867 http://dx.doi.org/10.1007/s40261-023-01291-6 |
Ejemplares similares
-
CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens
por: Ibragimova, M. K., et al.
Publicado: (2023) -
The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012) -
Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020) -
The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers
por: Najafi, Safa, et al.
Publicado: (2018) -
Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)